Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
62 hedge funds and large institutions have $72M invested in Sorrento Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 16 increasing their positions, 19 reducing their positions, and 10 closing their positions.
2,025% more call options, than puts
Call options by funds: $170K | Put options by funds: $8K
4% more capital invested
Capital invested by funds: $69.3M → $72M (+$2.7M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 68 → 62 (-6)
16% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 19
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$3.26M |
| 2 |
WCM
Wildcat Capital Management
New York
|
+$1.13M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$556K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$246K |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$164K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.11M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$805K |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$626K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$464K |
| 5 |
Millennium Management
New York
|
-$419K |
SRNE Hedge Fund Activity: Q2 2016 in Review
62 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q2 2016, worth a combined $72M — up 3.9% from $69.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of SRNE and 4 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 16 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $3.26M. The largest seller was TFS Capital, cutting an estimated $1.11M.
- 62 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q2 2016, down from 68 in Q1 2016.
- Funds reported $72M of Sorrento Therapeutics, Inc. stock for Q2 2016, up 3.9% quarter-over-quarter.
- 4 funds opened new Sorrento Therapeutics, Inc. positions in Q2 2016 and 10 closed out, a net change of -6 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q2 2016 was Avoro Capital Advisors, an estimated $3.26M added.
- The largest Sorrento Therapeutics, Inc. seller in Q2 2016 was TFS Capital, an estimated $1.11M sold.
Based on aggregated 13F filings for Q2 2016.